Pharmacyte Biotech, Inc. (PMCB) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Pharmacyte Biotech, Inc. on November 24, 2023, reporting events that occurred on November 20, 2023. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol "PMCB".
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes
The Board of Directors approved one-time compensatory grants to two senior officers on November 20, 2023, pursuant to the PharmaCyte Biotech, Inc. 2022 Equity Incentive Plan:
- Joshua N. Silverman (Interim CEO and Interim President): Received a grant consisting of $100,000 in cash and options to purchase 170,000 shares of common stock at an exercise price of $2.18 per share.
- Carlos A. Trujillo (Chief Financial Officer): Received a grant consisting of $50,000 in cash and options to purchase 85,000 shares of common stock at an exercise price of $2.18 per share.
For both grants, the options vest 50% on the grant date and 50% on the one-year anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items beyond the specific compensation grants detailed above.
Key Facts for Investor Verification
- Verify the total cash outflow of $150,000 for the immediate grants to the Interim CEO and CFO.
- Confirm the total number of new options issued (255,000 shares) and their impact on potential dilution.
- Note the exercise price of $2.18 per share relative to the current market price of the stock.
- Review the vesting schedule, noting that 50% of the options for both executives vested immediately on November 20, 2023.